We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Reduced Antioxidant Protection Leads to Neuron Loss in Parkinson's Disease

By LabMedica International staff writers
Posted on 13 Mar 2016
Lack of antioxidant protection in brain cells due to mutations that prevent the expression of the protein encoded by the oncogene DJ-1 (also known as Parkinson protein 7 or PARK7) has been linked to premature aging of neurons in Parkinson's disease patients.

The oncogene DJ-1 was identified originally as a suppressor of PTEN (phosphatase and tensin homolog), and loss-of-function mutations have been described as a causative factor in Parkinson's disease (PD). More...
While it was known that DJ-1 had an important function in cellular antioxidant responses, its role in the central metabolism of neurons remained to be clarified.

Investigators at the University of Luxembourg (Esch-sur-Alzette, Luxembourg) applied stable isotope assisted metabolic profiling to investigate the effect of a functional loss of DJ-1.

They reported in the February 1, 2016, online edition of the journal Neurobiology of Disease that DJ-1 deficient neuronal cells exhibited decreased glutamine influx and reduced serine biosynthesis. These two metabolic pathways provide the precursors glutamate, serine, and glycine for de novo synthesis of glutathione. In line with these metabolic flux changes, the investigators observed decreased glutathione levels and an impaired antioxidant response in DJ-1 deficient cells.

In addition, DJ-1 deficient mouse microglia showed a weak but constitutive pro-inflammatory activation. The combined effects of altered antioxidant metabolism and constitutive activation of glia cells raised the susceptibility of dopamine-producing neurons towards degeneration in patients harboring mutated DJ-1.

"Normally, microglial cells are only activated when something in the brain needs to be cleaned up, for instance during inflammation," said senior author Dr. Karsten Hiller, head of the metabolomics group at the University of Luxembourg. "However, if these cells are constantly active, as we discovered happens with the DJ-1 defect, this weakens the underlying neurons. We need the right amount of DJ-1. While in some forms of cancer there is too much DJ-1, in this case of Parkinson's disease, neurons do not have enough DJ-1 and die off."

Related Links:

University of Luxembourg



Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gold Member
Hematology Analyzer
Medonic M32B
Homocysteine Quality Control
Liquichek Homocysteine Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Industry

view channel
Image: The LIAISON NES molecular point-of-care platform (Photo courtesy of Diasorin)

Diasorin and Fisher Scientific Enter into US Distribution Agreement for Molecular POC Platform

Diasorin (Saluggia, Italy) has entered into an exclusive distribution agreement with Fisher Scientific, part of Thermo Fisher Scientific (Waltham, MA, USA), for the LIAISON NES molecular point-of-care... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.